Skip to Content
Morningstar

Eli Lilly and Co LLY

Morningstar Rating
Unlock
Stock XNYS Rating as of
$724.87 −7.33 (1.00%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Eli Lilly: Positive Tirzepatide Data in Obstructive Sleep Apnea Reinforces Drug's Massive Potential

Damien Conover

We are holding our fair value estimate for Eli Lilly steady after the company reported positive tirzepatide (Mounjaro/Zepbound) data in treating obstructive sleep apnea and obesity. We had largely expected the positive results, which support our robust peak annual sales forecast for the drug at over $60 billion annually across all indications. The solid data does help reinforce the company’s wide moat.

Read Full Report

Price vs Fair Value

View History
LLY is trading at a 49% premium.
Price
$745.69
Fair Value
$786.00
Uncertainty
High
1-Star Price
$892.00
5-Star Price
$886.00
Economic Moat
Hbng
Capital Allocation
Wwlzyprzcd

Bulls Say, Bears Say

Bulls

Lilly is developing a new Alzheimer’s drug (donanemab) that could become a major blockbuster, especially because the FDA appears to have a lower threshold for approval for this disease.

Bears

The risks to success for Alzheimer’s drug donanemab remain high both in clinical development and insurance coverage.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LLY is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$732.20
Day Range
$718.30–727.99
52-Week Range
$370.68–800.78
Bid/Ask
$720.65 / $727.60
Market Cap
$689.18 Bil
Volume/Avg
2.6 Mil / 3.1 Mil

Key Statistics

Price/Earnings (Normalized)
86.39
Price/Sales
19.19
Dividend Yield (Trailing)
0.63%
Dividend Yield (Forward)
0.70%
Total Yield
0.75%

Company Profile

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Growth
Total Number of Employees
43,000
Website
https://www.lilly.com

Competitors

Valuation

View More
Metric
LLY
MRK
NVO
Price/Earnings (Normalized)
 86.3984.6646.57
Price/Book Value
 63.898.5635.45
Price/Sales
 19.195.3816.77
Price/Cash Flow
 89.7521.2732.16
Price/Earnings
LLY
MRK
NVO

Financial Strength

Metric
LLY
MRK
NVO
Quick Ratio
 0.520.680.62
Current Ratio
 0.941.250.82
Interest Coverage
 14.132.33192.15
Quick Ratio
LLY
MRK
NVO

Profitability

Metric
LLY
MRK
NVO
Return on Assets (Normalized)
 10.22%3.59%30.82%
Return on Equity (Normalized)
 52.03%9.12%94.27%
Return on Invested Capital (Normalized)
 19.27%5.88%72.84%
Return on Assets
LLY
MRK
NVO
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - General Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
JNJ
Johnson & JohnsonRvbwlqgvsPrws$353.8 Bil
MRK
Merck & Co IncDgrmxhmqfFhqdf$321.5 Bil
ABBV
AbbVie IncKlnzttckxMztcw$296.2 Bil
AZN
AstraZeneca PLC ADRSqsrcmtmkDrhnp$219.1 Bil
NVS
Novartis AG ADRHplvhnjCcdkd$200.8 Bil
RHHBY
Roche Holding AG ADRLhryxgdhRymhc$196.3 Bil
AMGN
Amgen IncNtffdcfdklJnw$144.5 Bil
PFE
Pfizer IncLcpvhbvqkWkyq$143.0 Bil
SNY
Sanofi SA ADRYxsgfxfmFhnc$117.2 Bil

Sponsor Center